Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Roberson

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
International Journal of Radiation Oncology, Biology, Physics|January 5, 2005
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRIPatrick W McLaughlin, Vrinda Narayana, Amichay Meirovitz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2010
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modelingYuni K Dewaraja, Matthew J Schipper, Peter L Roberson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2014
Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab RadioimmunotherapyYuni K Dewaraja, Matthew J Schipper, Jincheng Shen, et al.
EJNMMI Physics|December 1, 2018
Impact of <sup>90</sup>Y PET gradient-based tumor segmentation on voxel-level dosimetry in liver radioembolizationJustin K Mikell, Ravi K Kaza, Peter L Roberson, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
International Journal of Radiation Oncology, Biology, Physics|January 5, 2005
Vessel-sparing prostate radiotherapy: dose limitation to critical erectile vascular structures (internal pudendal artery and corpus cavernosum) defined by MRIPatrick W McLaughlin, Vrinda Narayana, Amichay Meirovitz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 18, 2010
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modelingYuni K Dewaraja, Matthew J Schipper, Peter L Roberson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2014
Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab RadioimmunotherapyYuni K Dewaraja, Matthew J Schipper, Jincheng Shen, et al.
EJNMMI Physics|December 1, 2018
Impact of <sup>90</sup>Y PET gradient-based tumor segmentation on voxel-level dosimetry in liver radioembolizationJustin K Mikell, Ravi K Kaza, Peter L Roberson, et al.
Pageof 3